| ABSTRACT Objective:To systematically assess the clinical effectiveness and safety of Huachansu injection combined with transcatheter arterial chemoembolization (TACE) in the treatment of liver cancer. Methods:A thorough and systematic retrieval of randomized controlled trials (RCTs) which regarding Huachansu injection combined with TACE in the treatment of liver cancer was conducted by using literature databases. Quality of included RCTs was evaluated by the risk of bias assessment tool, and then the required information was extracted and Meta analyzed by RevMan 5.3 software. Results:A total of 11 RCTs with 783 participants were included in this study. In the meta analysis, Huachansu injection combined with TACE could achieve a better effect than receiving TACE therapy alone in respect of objective response rate[RR=1.36, 95%CI(1.16,1.58), P=0.000 1], improvement of life quality [RR=1.96, 95%CI(1.56,2.47),P<0.000 01]. In addition, Huachansu injection could decrease serum total bilirubin, alanine aminotransferase and so on. Conclusion:Huachansu injection combined with TACE was effective in treating liver cancer, but its safety needed to be further explored, limited by the number and quality of the literature, while our conclusion should be confirmed by more large scale randomized controlled of double blind RCTs. |
